Suraksha Diagnostic Ltd
NSE: SURAKSHA BSE: 544293Healthcare
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
₹298
52W: ₹224 — ₹354
PE 43.9 · Book ₹45 · +562% vs bookMarket Cap₹1,554 Cr
Stock P/E43.9Price to Earnings
ROCE18.5%Return on Capital
ROE17.1%Return on Equity
Div. Yield0%Face Value ₹2
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 9.60% over past five years.
- −Company has a low return on equity of 13.3% over last 3 years.
Shareholding Pattern
Promoters49.1%
FIIs13.46%
DIIs23.14%
Public14.31%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 48.78% | 48.78% | 48.89%▲0.1 | 48.98%▲0.1 | 49%▲0.0 | 49.1%▲0.1 |
| FIIs | 15.39% | 14.46%▼0.9 | 13.95%▼0.5 | 13.73%▼0.2 | 13.46%▼0.3 | 13.46% |
| DIIs | 20.43% | 22.05%▲1.6 | 22.37%▲0.3 | 21.98%▼0.4 | 22.57%▲0.6 | 23.14%▲0.6 |
| Public | 15.39% | 14.71%▼0.7 | 14.79%▲0.1 | 15.3%▲0.5 | 14.98%▼0.3 | 14.31%▼0.7 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60.05 | 51.45 | 55.37 | 60.43 | 65.95 | 58.57 | 64.15 | 70.28 | 76.26 | 75.58 |
| Expenses | 39 | 35.87 | 35.44 | 39.32 | 42.39 | 40.48 | 44.33 | 46.45 | 52.29 | 52.39 |
| Operating Profit | 21.05 | 15.58 | 19.93 | 21.11 | 23.56 | 18.09 | 19.82 | 23.83 | 23.97 | 23.19 |
| OPM % | 35.05% | 30.28% | 35.99% | 34.93% | 35.72% | 30.89% | 30.9% | 33.91% | 31.43% | 30.68% |
| Net Profit | 8.65 | 4.93 | 6.84 | 8.33 | 10.75 | 6.36 | 8.01 | 9.85 | 9.36 | 8.14 |
| EPS ₹ | 125.36 | 71.45 | 99.13 | 1.93 | 2.49 | 1.22 | 1.54 | 1.89 | 1.8 | 1.56 |
AI Insights
Revenue Trend
TTM revenue at ₹286Cr, up 14.9% YoY. OPM at 32%.
Debt Position
Borrowings at ₹115Cr. Debt-to-equity ratio: 0.51x. Moderate leverage.
Capex Cycle
CWIP at ₹2Cr (1% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 23.14% (+2.71pp change). FIIs: 13.46% (-1.93pp change). Promoters hold 49.1%.
Margin & Efficiency
ROCE improving from 0% (Mar 2018) to 18% (Mar 2025). Working capital days: -14.
Valuation
PE 43.9x with 18.5% ROCE. Price is 562% above book value of ₹45. Dividend yield: 0%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Intimation of the schedule of Analysts/Institutional Investors/ Organisations meeting to be held on Friday, 22 May 2026 at 12:00 P.M. (IST).
- Board Meeting Intimation for Inter-Alia, Considering And Approving Audited (Standalone And Consolidated) Financial Results Of The Company For Quarter And FY 2025-26 And To Consider Recommendation Of Dividend, If Any, On Equity Shares Of Company For FY 2025-26. 13 May - Board meeting on 21 May 2026 to approve FY26 audited results and consider dividend.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - The Certificate received under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 from M/s. KFin Technologies Limited, the Registrar & Share Transfer Agent of …
- Closure of Trading Window 20 Mar - Trading window closed from 01 Apr 2026 until 48 hours after audited results for quarter/year ended 31 Mar 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Mar - Intimation of the schedule of Analysts/ Institutional Investors/ Organisations meeting to be held on Monday, 09 March 2026 at 10:00 am
- Financial Year 2025 from bse
- Rating update 8 Oct 2025 from crisil
- Transcript